Actinium Pharmaceuticals Inc (NYSE MKT:ATNM) — Market Cap & Net Worth
Market Cap & Net Worth: Actinium Pharmaceuticals Inc (ATNM)
Actinium Pharmaceuticals Inc (NYSE MKT:ATNM) has a market capitalization of $37.02 Million ($37.02 Million) as of September 17, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #23114 globally and #5051 in its home market, demonstrating a -7.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Actinium Pharmaceuticals Inc's stock price $1.18 by its total outstanding shares 31374994 (31.37 Million). Also see Actinium Pharmaceuticals Inc total assets for a full breakdown of the balance sheet.
Actinium Pharmaceuticals Inc Market Cap History: 2015 to 2026
Actinium Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $3.04 Billion to $37.02 Million (-31.85% CAGR). Also see Actinium Pharmaceuticals Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Actinium Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Actinium Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Actinium Pharmaceuticals Inc (ATNM) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
474.11x
Actinium Pharmaceuticals Inc's market cap is 474.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $244.72 Million | $622.00K | -$22.21 Million | 393.45x | N/A |
| 2021 | $188.56 Million | $1.14 Million | -$24.77 Million | 164.83x | N/A |
| 2022 | $334.14 Million | $1.03 Million | -$33.02 Million | 324.41x | N/A |
| 2023 | $159.38 Million | $81.00K | -$48.82 Million | 1967.72x | N/A |
| 2025 | $42.67 Million | $90.00K | -$33.89 Million | 474.11x | N/A |
Competitor Companies of ATNM by Market Capitalization
Companies near Actinium Pharmaceuticals Inc in the global market cap rankings as of September 17, 2026. Review ATNM intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Actinium Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Actinium Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Actinium Pharmaceuticals Inc's market cap moved from $3.04 Billion to $ 37.02 Million, with a yearly change of -31.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $37.02 Million | -13.24% |
| 2025 | $42.67 Million | +7.94% |
| 2024 | $39.53 Million | -75.20% |
| 2023 | $159.38 Million | -52.30% |
| 2022 | $334.14 Million | +77.20% |
| 2021 | $188.56 Million | -22.95% |
| 2020 | $244.72 Million | +19.43% |
| 2019 | $204.91 Million | -43.75% |
| 2018 | $364.26 Million | -41.68% |
| 2017 | $624.61 Million | -24.16% |
| 2016 | $823.59 Million | -72.91% |
| 2015 | $3.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Actinium Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.02 Million USD |
| MoneyControl | $37.02 Million USD |
| MarketWatch | $37.02 Million USD |
| marketcap.company | $37.02 Million USD |
| Reuters | $37.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular… Read more